Familial hypercholesterolaemia and COVID-19: A two-hit scenario for endothelial dysfunction amenable to treatment
Tài liệu tham khảo
Wilemon, 2020, Reducing the clinical and public health burden of familial hypercholesterolemia: a global call to action, JAMA Cardiol, 5, 217, 10.1001/jamacardio.2019.5173
1999
Brown, 1981, Regulation of plasma cholesterol by lipoprotein receptors, Science, 212, 628, 10.1126/science.6261329
Tada, 2015, Assessment of coronary atherosclerosis in patients with familial hypercholesterolemia by coronary computed tomography angiography, Am. J. Cardiol., 115, 724, 10.1016/j.amjcard.2014.12.034
Ose, 1999, An update on familial hypercholesterolaemia, Ann. Med., 31, 13, 10.1080/07853890.1999.11904394
Humphries, 2018, Coronary heart disease mortality in treated familial hypercholesterolaemia: update of the UK Simon Broome FH register, Atherosclerosis, 274, 41, 10.1016/j.atherosclerosis.2018.04.040
Luirink, 2019, 20-Year follow-up of statins in children with familial hypercholesterolemia N, Engl. J. Med., 381, 1547, 10.1056/NEJMoa1816454
Wang, 2020, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China, J. Am. Med. Assoc., 323, 1061, 10.1001/jama.2020.1585
Sijbrands, 2001, Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study, BMJ, 322, 1019, 10.1136/bmj.322.7293.1019
Vuorio, 1997, Familial hypercholesterolemia in the Finnish North Karelia: a molecular, clinical, and genealogical study, Arterioscler. Thromb. Vasc. Biol., 17, 3127, 10.1161/01.ATV.17.11.3127
Netea, 1996, Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe gram-negative infections, J. Clin. Invest., 97, 1366, 10.1172/JCI118556
Barkas, 2020, Diet and cardiovascular disease risk among individuals with familial hypercholesterolemia: systematic review and meta-analysis, Nutrients, 12, 2436, 10.3390/nu12082436
Khovidhunkit, 2000, Infection and inflammation‐induced proatherogenic changes of lipoproteins, J. Infect. Dis., 181, S462, 10.1086/315611
Kovanen, 2005, Drug therapies to prevent coronary plaque rupture and erosion: present and future
Chow, 2020, Acute cardiovascular events associated with influenza in hospitalized adults: a cross-sectional study, Ann. Intern. Med., 10.7326/M20-1509
Kontula, 1999, Association of seropositivity for Chlamydia pneumoniae and coronary artery disease in heterozygous familial hypercholesterolaemia, Lancet, 354, 46, 10.1016/S0140-6736(99)01691-8
Hu, 1999, The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae, J. Clin. Invest., 103, 747, 10.1172/JCI4582
Nieto, 1997, Cytomegalovirus infection, lipoprotein(a), and hypercoagulability: an atherogenic link?, Arterioscler. Thromb. Vasc. Biol., 17, 1780, 10.1161/01.ATV.17.9.1780
DiMinno, 1986, Increased fibrinogen binding to platelets from patients with familial hypercholesterolemia, Arteriosclerosis, 6, 203, 10.1161/01.ATV.6.2.203
Vuorio, 2020, Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities, J. Intern. Med., 287, 2, 10.1111/joim.12981
Apostolou, 2010, Acute infection with Epstein-Barr virus is associated with atherogenic lipid changes, Atherosclerosis, 212, 607, 10.1016/j.atherosclerosis.2010.06.006
Sorensen, 1994, Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level, J. Clin. Invest., 93, 50, 10.1172/JCI116983
Charakida, 2009, Inflammatory and thrombotic processes are associated with vascular dysfunction in children with familial hypercholesterolemia, Atherosclerosis, 204, 532, 10.1016/j.atherosclerosis.2008.09.025
Vuorio A, Kovanen PT. Prevention of endothelial dysfunction and thrombotic events in COVID-19 patients with familial hypercholesterolemia. J. Clin. Lipidol. Published 15 Jun 2020. 10.1016/j.jacl.2020.06.006.
Libby, 2020, COVID-19 is, in the end, an endothelial Disease, Eur. Heart J., 41, 3038, 10.1093/eurheartj/ehaa623
Nordestgaard, 2013, Eur. Heart J., 34, 10.1093/eurheartj/eht273
Sturm, 2018, Clinical genetic testing for familial hypercholesterolemia: JACC Scientific Expert Panel, J. Am. Coll. Cardiol., 72, 662, 10.1016/j.jacc.2018.05.044
Steinberg, 1997, Endothelial dysfunction is associated with cholesterol levels in the high normal range in humans, Circulation, 96, 3287, 10.1161/01.CIR.96.10.3287
Vuorio, 2016, Rescue therapy with PCSK9 inhibitors for patients with delayed diagnosis of heterozygous familial hypercholesterolemia: redressing the balance of missed opportunities, J. Clin. Lipidol., 10, 1278, 10.1016/j.jacl.2016.07.003
Tada, 2015, Assessment of coronary atherosclerosis in patients with familial hypercholesterolemia by coronary computed tomography angiography, Am. J. Cardiol., 115, 724, 10.1016/j.amjcard.2014.12.034
Caballero, 2012, Detection of subclinical atherosclerosis in familial hypercholesterolemia using non-invasive imaging modalities, Atherosclerosis, 222, 468, 10.1016/j.atherosclerosis.2012.02.043
Libby, 2019, Reassessing the mechanisms of acute coronary syndromes, Circ. Res., 124, 150, 10.1161/CIRCRESAHA.118.311098
Sahebkar, 2016, Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms, Br. J. Clin. Pharmacol., 81, 1175, 10.1111/bcp.12905
Pradhan, 2018, Residual inflammatory risk on treatment with PCSK9 inhibition on statin therapy, Circulation, 138, 141, 10.1161/CIRCULATIONAHA.118.034645
Humphries, 2019, Coronary heart disease mortality in severe vs. non-severe familial hypercholesterolaemia in the Simon Broome Register, Atherosclerosis, 281, 207, 10.1016/j.atherosclerosis.2018.11.014
Varga, 2020, Endothelial cell infection and endotheliitis in COVID-19, Lancet, 395, 1417, 10.1016/S0140-6736(20)30937-5
Khovidhunkit, 2004, Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host, J. Lipid Res., 45, 1169, 10.1194/jlr.R300019-JLR200
Boffa, 2019, Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease, Nat. Rev. Cardiol., 16, 305, 10.1038/s41569-018-0153-2
Besseling, 2015, Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus, J. Am. Med. Assoc., 313, 1029, 10.1001/jama.2015.1206
Barron, 2020, Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study, Lancet Diabetes Endocrinol, 20
Vuorio, 2016, Statins and new‐onset diabetes mellitus – a risk lacking in familial hypercholesterolaemia, J. Intern. Med., 279, 358, 10.1111/joim.12405
Humphries, 2018, The UK paediatric familial hypercholesterolaemia register: statin-related safety and 1-year growth data, J. Clin. Lipidol., 12, 25, 10.1016/j.jacl.2017.11.005
Pérez de Isla, 2016, Coronary heart disease, peripheral arterial disease, and stroke in familial hypercholesterolaemia: insights from the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study), Arterioscler. Thromb. Vasc. Biol., 36, 2004, 10.1161/ATVBAHA.116.307514
Kunutsor, 2020, Incidence of venous and arterial thromboembolic complications in COVID-19: a systematic review and meta-analysis, Thromb. Res., 196, 27, 10.1016/j.thromres.2020.08.022
Lodigiani, 2020, Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy, Thromb. Res., 191, 9, 10.1016/j.thromres.2020.04.024
Bilaloglu, 2020, Thrombosis in hospitalized patients with COVID-19 in a New York city health system, J. Am. Med. Assoc., 324, 799, 10.1001/jama.2020.13372
Beyrouti, 2020, Characteristics of ischaemic stroke associated with COVID-19, J. Neurol. Neurosurg. Psychiatry, 91, 889, 10.1136/jnnp-2020-323586
Oxley, 2020, Large-vessel stroke as a presenting feature of Covid-19 in the young, N. Engl. J. Med., 382, e60, 10.1056/NEJMc2009787
Rothstein, 2020, Acute cerebrovascular events in hospitalized COVID-19 patients, Stroke, 10.1161/STROKEAHA.120.030995
Andjelkovic, 2019, Endothelial targets in stroke, Arterioscler. Thromb. Vasc. Biol., 39, 2240, 10.1161/ATVBAHA.119.312816
Mao, 2020, Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China, JAMA Neurology, 77, 683, 10.1001/jamaneurol.2020.1127
Ntaios G, Michel P, Georgiopoulos G, Guo Y, Li W, Xiong J et al. Characteristics and outcomes in patients with COVID-19 and acute ischemic stroke: the global COVID-19 stroke registry. Stroke. Published 9 July 2020. doi: 10.1161/STROKEAHA.120.031208.
Kaste, 1988, Risk of brain infarction in familial hypercholesterolemia, Stroke, 19, 1097, 10.1161/01.STR.19.9.1097
Cron, 2020, Coronavirus is the trigger, but the immune response is deadly, Lancet Rheumatol, 2, e370, 10.1016/S2665-9913(20)30165-X
Paliogiannis, 2020, D-Dimer concentrations and COVID-19 severity: a systematic review and meta-analysis, Front. Public Health., 4, 432, 10.3389/fpubh.2020.00432
Shakoory, 2016, Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial, Crit. Care Med., 44, 275, 10.1097/CCM.0000000000001402
Cummings, 2020, Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study, Lancet, 395, 1763, 10.1016/S0140-6736(20)31189-2
Terpos, 2020, Hematological findings and complications of COVID‐19, Am. J. Hematol., 95, 834, 10.1002/ajh.25829
Moore, 2020, Cytokine release syndrome in severe COVID-19, Science, 368, 473, 10.1126/science.abb8925
Léonard-Lorant, 2020, Acute pulmonary embolism in COVID-19 patients on CT angiography and relationship to D-dimer levels, Radiology, 293, E189, 10.1148/radiol.2020201561
Mucha, 2020, Coagulopathy in COVID-19. Cleve, Clin. J. Med. Off.
Yuan, 2015, Statins may decrease the fatality rate of Middle East respiratory syndrome infection, mBio, 6, 10.1128/mBio.01120-15
Vandermeer, 2012, Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study, J. Infect. Dis., 205, 13, 10.1093/infdis/jir695
Mehra, 2020, Cardiovascular disease, drug therapy, and mortality in Covid-19, N. Engl. J. Med., 382, e102, 10.1056/NEJMoa2007621
de Spiegeleer, 2020, The effects of ARBs, ACEIs and statins on clinical outcomes of COVID-19 infection among nursing home residents, J. Am. Med. Dir. Assoc., 21, 909, 10.1016/j.jamda.2020.06.018
Loppnow, 2011, Statins potently reduce the cytokine‐mediated IL6 release in SMC/MNC cocultures, J. Cell Mol. Med., 15, 994, 10.1111/j.1582-4934.2010.01036.x
de Bont, 2006, LPS-induced release of IL-1 beta, IL-1Ra, IL-6, and TNF-alpha in whole blood from patients with familial hypercholesterolemia: no effect of cholesterol-lowering treatment, J. Interferon Cytokine Res., 26, 101, 10.1089/jir.2006.26.101
Wiklund, 2002, Effects of simvastatin and atorvastatin on inflammation markers in plasma, J. Intern. Med., 251, 338, 10.1046/j.1365-2796.2002.00966.x
Cicek, 2016, Statins and IL-1β, IL-10, and MPO levels in gingival crevicular fluid: preliminary results, Inflammation, 39, 1547, 10.1007/s10753-016-0390-7
Liberale, 2019, IL-1β and statin treatment in patients with myocardial infarction and diabetic cardiomyopathy, J. Clin. Med., 8, 1764, 10.3390/jcm8111764
Schol‐Gelok, 2018, Clinical effects of antiplatelet drugs and statins on D‐dimer levels, Eur. J. Clin. Invest., 48, 10.1111/eci.12944
Adams, 2013, Statin therapy and levels of hemostatic factors in a healthy population: the Multi‐Ethnic Study of Atherosclerosis, J. Thromb. Haemostasis, 11, 1078, 10.1111/jth.12223
Dujovne, 2000, Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients, Am. J. Cardiol., 85, 350, 10.1016/S0002-9149(99)00745-6
Sbarouni, 2000, Effects of simvastatin or hormone replacement therapy, or both, on fibrinogen, factor VII, and plasminogen activator inhibitor levels in postmenopausal women with proven coronary artery disease, Am. J. Cardiol., 86, 80, 10.1016/S0002-9149(00)00831-6
Undas, 2005, Statins and blood coagulation, Arterioscler. Thromb. Vasc. Biol., 25, 287, 10.1161/01.ATV.0000151647.14923.ec
Undas, 2014, Anticoagulant effects of statins and their clinical implications, Thromb. Haemostasis, 111, 392, 10.1160/TH13-08-0720
Ekholm, 2015, Haemostatic and inflammatory alterations in familial hypercholesterolaemia, and the impact of angiotensin II infusion, J. Renin-Angiotensin-Aldosterone Syst. JRAAS, 16, 328, 10.1177/1470320315575848
Meretoja, 2014, Stroke thrombolysis: save a minute, save a day, Stroke, 45, 1053, 10.1161/STROKEAHA.113.002910
Huxley, 2003, Risk of fatal stroke in patients with treated familial hypercholesterolemia: a prospective registry study, Stroke, 34, 22, 10.1161/01.STR.0000047123.14312.3E
Barkas, 2015, Statins decrease the risk of stroke in individuals with heterozygous familial hypercholesterolemia: a systematic review and meta-analysis, Atherosclerosis, 243, 60, 10.1016/j.atherosclerosis.2015.08.038
Powers, 2019, Stroke, 50, e344, 10.1161/STROKEAHA.118.022606
Kow CS, Hasan SS. Meta-analysis of effectiveness of statins in patients with severe COVID-19 Am. J. Cardiol.. Published 12 Aug 2020;doi:10.1016/j.amjcard.2020.08.004.
Zhang XJ, Qin JJ, Cheng X, Shen L, Zhao Y-CX, Yuan Y et al. In-hospital Use of Statins Is Associated with Reduced Mortality Among Individuals with COVID-19. Cell. Metab. Published 24 June 2020. doi.org/10.1016/j.cmet.2020.06.015.
Grasselli, 2020, Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern. Med., 10.1001/jamainternmed.2020.3539
Iqbal Z, Ho JH, Adam S, France M, Syed A, Neely D et a. Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK, Atherosclerosis, https://doi.org/10.1016/j.atherosclerosis.2020.09.008.
Banach, 2020, FH Europe and the International Lipid Expert Panel (ILEP). Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic, Pharmacol. Res., 158, 10.1016/j.phrs.2020.104891
Choudry, 2020, High thrombus burden in patients with COVID-19 presenting with ST-Segment elevation myocardial infarction, J. Am. Coll. Cardiol., 76, 1168, 10.1016/j.jacc.2020.07.022
Tsimikas, 2020, Statins and increases in Lp(a): an inconvenient truth that needs attention, Eur. Heart J., 41, 192, 10.1093/eurheartj/ehz776
Vuorio, 2020, PCSK9 inhibitors for COVID-19: an opportunity to enhance the antiviral action of interferon in patients with hypercholesterolemia, J. Intern. Med.
Vuorio, 2020, Familial hypercholesterolaemia and COVID‐19: triggering of increased sustained cardiovascular risk, J. Intern. Med., 287, 746, 10.1111/joim.13070
Sjouke, 2015, Homozygous autosomal dominant hypercholesterolaemia: prevalence, diagnosis and current and future treatment perspectives, Curr. Opin. Lipidol., 26, 200, 10.1097/MOL.0000000000000179
Cuchel, 2014, Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society, Eur. Heart J., 35, 2146, 10.1093/eurheartj/ehu274
Clerkin, 2020, COVID-19 and cardiovascular disease, Circulation, 141, 1648, 10.1161/CIRCULATIONAHA.120.046941
Jeon, 2018, Cholesterol is important for the entry process of porcine delta-coronavirus, Arch. Virol., 163, 3119, 10.1007/s00705-018-3967-7
Holven, 2014, Subjects with familial hypercholesterolemia are characterized by an inflammatory phenotype despite long-term intensive cholesterol lowering treatment, Atherosclerosis, 233, 561, 10.1016/j.atherosclerosis.2014.01.022
Kraft, 2000, Lipoprotein(a) in homozygous familial hypercholesterolemia, Arterioscler. Thromb. Vasc. Biol., 20, 522, 10.1161/01.ATV.20.2.522
Pourahmad, 2020, Efficacy of plasmapheresis and immunoglobulin replacement therapy (IVIG) on patients with COVID-19. SN, Compr. Clin. Med., 2, 1407, 10.1007/s42399-020-00438-2
Brown, 1978, Prenatal diagnosis of homozygous familial hypercholesterolaemia. Expression of a genetic receptor disease in utero, Lancet, 8063, 526, 10.1016/S0140-6736(78)90552-4
Vuorio, 1997, Neonatal diagnosis of familial hypercholesterolemia in newborns born to a parent with a molecularly defined heterozygous familial hypercholesterolemia, Arterioscler. Thromb. Vasc. Biol., 17, 3332, 10.1161/01.ATV.17.11.3332
de Jongh, 2002, Family history of cardiovascular events and endothelial dysfunction in children with familial hypercholesterolemia, Atherosclerosis, 163, 193, 10.1016/S0021-9150(02)00003-5
Bifulco M, Gazzerro P. Statin therapy in COVID-19 infection: much more than a single pathway. Eur. Heart J. Cardiovasc. Pharmacother. Published 12 Juni 2020. doi:10.1093/ehjcvp/pvaa055.
Castiglione, 2020, Statin therapy in COVID-19 infection, Eur. Heart J. Cardiovasc. Pharmacother., 6, 258, 10.1093/ehjcvp/pvaa042
Dashti‐Khavidaki, 2020, Considerations for statin therapy in patients with COVID‐19, Pharmacotherapy, 40, 484, 10.1002/phar.2397
Mehta, 1998, Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease, J. Am. Coll. Cardiol., 31, 1217, 10.1016/S0735-1097(98)00093-X
Vuorio, 2019, Statins for children with familial hypercholesterolemia, Cochrane Database Syst. Rev., 11
Rudski, 2020, Multimodality imaging in evaluation of cardiovascular complications in patients with COVID-19: JACC Scientific Expert Panel, J. Am. Coll. Cardiol., 76, 1345, 10.1016/j.jacc.2020.06.080
Vuorio A, Kovanen PT. Statins as adjuvant therapy for COVID-19 to calm the stormy immunothrombosis and beyond. Published 4 Dec 2020. Front. Pharmacol.. doi: 10.3389/fphar.2020.579548.